NCT02855450 - Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions

Glaucoma

Interventions

DRUG

rhNGF

Recombinant Human Nerve Growth Factor 180μg/ml (one 35 μl drop equals to 6.30 μg of rhNGF) reconstituted solution three times a day (TID) for 8 weeks of treatment.

DRUG

Vehicle

Ophthalmic Placebo solution of the same composition as the test product with the exception of rhNGF reconstituted solution times a day (TID) for 8 weeks of treatment.

Trial Locations (1)

94303

Byers Eye Institute at Stanford University, Palo Alto